{"pmid": "12506177", "sentences": {"sent_1": {"Section": "", "text": "PATIENTS AND METHODS : Patients with prostate cancer who had undergone previous definitive surgical or radiation therapy with nonmetastatic , recurrent disease as manifested by a rising PSA between 0.4 ng / mL and 6.0 ng / mL were enrolled on this phase II trial .", "entities": {"entity_1": {"text": "prostate cancer", "class": "Participant", "negation": 0, "UMLS": "C0376358:prostate cancer,", "index": 1, "start": 6}, "entity_2": {"text": "surgical or radiation therapy", "class": "Participant", "negation": 0, "UMLS": "C0034619:radiation therapy,", "index": 2, "start": 13}, "entity_3": {"text": "nonmetastatic", "class": "Participant", "negation": 0, "UMLS": "", "index": 3, "start": 18}, "entity_4": {"text": "recurrent disease", "class": "Participant", "negation": 0, "UMLS": "C0277556:recurrent disease,", "index": 4, "start": 20}, "attribute_1": {"text": "0.4 ng / mL", "class": "measure", "negation": 0, "UMLS": "", "index": 5, "start": 29}, "attribute_2": {"text": "6.0 ng / mL", "class": "measure", "negation": 0, "UMLS": "", "index": 6, "start": 34}}, "relations": {}}, "sent_2": {"Section": "", "text": "Patients received 250 micro g/m ( 2 ) / day of subcutaneous GM - CSF on days 1 through 14 of a 28 - day cycle .", "entities": {"attribute_3": {"text": "250 micro g/m ( 2 ) / day", "class": "measure", "negation": 0, "UMLS": "C1561538:day,", "index": 1, "start": 2}, "entity_5": {"text": "subcutaneous GM - CSF", "class": "Intervention", "negation": 0, "UMLS": "", "index": 2, "start": 11}}, "relations": {}}, "sent_3": {"Section": "", "text": "PSA was measured at day 1 of each cycle .", "entities": {"entity_6": {"text": "PSA", "class": "Outcome", "negation": 0, "UMLS": "", "index": 1, "start": 0}}, "relations": {}}}}